ASH 2023 Myeloid Recap With Anand Patel, MD

By Blood Cancer Talks - Last Updated: March 4, 2024

In this episode of “Blood Cancer Talks,” Anand Patel, MD, Assistant Professor of Medicine at the University of Chicago, joins hosts Raj Chakraborty, MD; Ashwin Kishtagari, MD; and Edward Cliff, MD, to discuss the top abstracts in the myeloid space presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.

Dr. Patel and the hosts first discuss the TRANSFORM-1 study, a randomized, multicenter, phase III study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis (MF).

They also discuss the following studies:

  • MANIFEST-2, a phase III study of pelabresib in combination with ruxolitinib for janus kinase inhibitor treatment-naïve patients with MF
  • AUGMENT-101, which studied revumenib monotherapy in patients with relapsed or refractory KMT2Ar acute lymphoblastic leukemia and acute myeloid leukemia (AML)
  • The FILO study, which looked at treatment-free remission and overall survival in patients with AML who stopped venetoclax and/or azacitidine

This podcast originally appeared on Blood Cancer Talks. 

Editorial Board